HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Potsaid, M. S. Articles by Zamenhof, R. G. Search for Related Content PubMed PubMed Citation Articles by Potsaid, M. S. Articles by Zamenhof, R. G.

[³²P] Diphosphonate Dose Determination in Patients with Bone Metastases from Prostatic Carcinoma

Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
Procter and Gamble Company, Cincinnati, Ohio

Correspondence: For reprints contact: Majic S. Potsaid, Nuclear Medicine Div., Dept. of Radiology, Massachusetts General Hospital, Boston, MA 02114.

ABSTRACT

In an initial safety study, phosphorus-32 (as diphosphonate) was administered intravenously to five patients with painful bone metastases from prostatic carcinoma; two patients received 9 mCi and three were given 3 mCi. Hematological, biochemical, ECG, x-ray, bone-scan data, and clinical observation, were followed for 2 mo. At both dose levels, bone-marrow depression was noted. One of the patients, who received 9 mCi, had only a slight dip in the leveLs of circulating white blood cells and platelets. The other 9-mCi patient was the only one with discrete metastases by bone scan; he had bone-marrow depression, from which he recovered, and was the only one of the five who had relief of bone pain.

FOOTNOTES

^* Present address: Dept. of Surgery, Div. of Urology, University of Mississippi Medical Ctr., 2500 N. State St., Jackson, MS 39216.

This article has been cited by other articles:

				A. Bishayee, D. V. Rao, S. C. Srivastava, L. G. Bouchet, W. E. Bolch, and R. W. Howell Marrow-Sparing Effects of 117mSn(4+)Diethylenetriaminepentaacetic Acid for Radionuclide Therapy of Bone Cancer J. Nucl. Med., December 1, 2000; 41(12): 2043 - 2050. [Abstract] [Full Text] [PDF]